In the search for treatments for COVID-19, many researchers are focusing their attention on a specific protein that allows the virus to infect human cells. Called the angiotensin-converting enzyme 2, or ACE2 "receptor," the ...
May 14, 2020
1
6
Evidence from a large study of several thousand patients shows that men have higher concentrations of angiotensin-converting enzyme 2 (ACE2) in their blood than women. Since ACE2 enables the coronavirus to infect healthy ...
May 11, 2020
0
600
(HealthDay)—Angiotensin-converting enzyme inhibitor (ACEI) and/or angiotensin receptor blocker (ARB) use is not associated with COVID-19 test positivity, according to a study published online May 5 in JAMA Cardiology.
May 8, 2020
0
2
Despite concerns expressed by some experts, common high blood pressure drugs did not increase the risk of contracting COVID-19—or of developing severe disease—in a study of 12,594 patients.
May 1, 2020
0
417
(HealthDay)—For patients with hypertension hospitalized with COVID-19 infections, angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs) are not associated with the severity or mortality of ...
Apr 23, 2020
0
1
A new trial led by the Perelman School of Medicine at the University of Pennsylvania will evaluate whether the use of medications to treat high blood pressure affect outcomes among patients who are prescribed the medication ...
Apr 16, 2020
0
56
Patients with underlying health conditions such as hypertension, heart failure, and chronic kidney disease are at increased risk of severe coronavirus disease 2019 (COVID-19). Physicians, healthcare professionals, researchers, ...
Mar 31, 2020
2
134
(HealthDay)—The new coronavirus may be a respiratory bug, but it's becoming clear that some severely ill patients sustain heart damage. And it may substantially raise their risk of death, doctors in China are reporting.
Mar 26, 2020
0
0
James Diaz, MD, MHA, MPH & TM, Dr. PH, Professor and Head of Environmental Health Sciences at LSU Health New Orleans School of Public Health, has proposed a possible explanation for the severe lung complications being seen ...
Mar 23, 2020
2
9430
(HealthDay)—Most estimates show no differences in effectiveness between classes of antihypertensive agents, according to a systematic, multinational, large-scale analysis published online Oct. 24 in The Lancet.
Nov 1, 2019
0
1
